|14.40||+0.8800||+6.51%||Vol 464.61K||1Y Perf -53.31%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||54.57||Analyst Rating||Strong Buy 1.23|
|Potential %||278.96||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★+ 53.82|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||8.88||Earnings Rating||Strong Buy|
|Market Cap||610.87M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.06|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||194.10K|
|Avg. Monthly Volume||391.48K|
|Avg. Quarterly Volume||316.01K|
Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 14.4 per share at the end of the most recent trading day (a 6.51% change compared to the prior day closing price) with a volume of 464.61K shares and market capitalization of 610.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.
The one-year performance of Bicycle Therapeutics plc stock is -53.31%, while year-to-date (YTD) performance is -51.35%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.54 and 33.49, which gives BCYC stock a 52-week price range ratio of 8.88%
Bicycle Therapeutics plc currently has a PE ratio of -9.20, a price-to-book (PB) ratio of 3.22, a price-to-sale (PS) ratio of 79.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.75%, a ROC of -37.45% and a ROE of -46.42%. The company’s profit margin is -%, its EBITDA margin is -641.80%, and its revenue ttm is $11.28 Million , which makes it $0.38 revenue per share.
Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.06 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.23), with a target price of $54.57, which is +278.96% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.40, ATR14 : 1.16, CCI20 : 29.95, Chaikin Money Flow : -0.15, MACD : -0.88, Money Flow Index : 40.79, ROC : 8.35, RSI : 45.08, STOCH (14,3) : 58.13, STOCH RSI : 1.00, UO : 43.63, Williams %R : -41.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Sold 2 248 shares of value $61 773 ), Crockett Nigel (Sold 3 141 shares of value $81 933 ), Dominic Smethurst (Sold 1 801 shares of value $52 337 ), Keen Nicholas (Sold 2 744 shares of value $73 410 ), Kevin Lee (Sold 7 486 shares of value $205 729 ), Lee H. Kalowski (Sold 2 191 shares of value $60 681 ), Lee Kevin (Sold 10 454 shares of value $272 729 ), Michael Skynner (Sold 2 248 shares of value $61 773 ), Milnes Alistair (Sold 3 141 shares of value $81 933 ), Nicholas Keen (Sold 2 136 shares of value $59 536 ), Nigel Crockett (Sold 2 248 shares of value $61 773 ), Skynner Michael (Sold 3 141 shares of value $81 933 ), Smethurst Dominic (Sold 1 801 shares of value $52 337 ), Thompson Travis Alvin (Sold 61 shares of value $1 531 ), Travis Alvin Thompson (Sold 54 shares of value $1 080 )
Tue, 12 Sep 2023 04:25 GMT Bicycle Therapeutics (BCYC) Gets a Buy from JMP Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.